![]() ![]() While its user friendly interface enables docking calculation and results evaluation carried out by researchers coming from all fields of biochemistry, DockingServer also provides full control on the setting of specific parameters of ligand and protein set up and docking calculations for more advanced users. View source version on businesswire.DockingServer offers a web-based, easy to use interface that handles all aspects of molecular docking from ligand and protein set-up. The current Flagship ecosystem comprises 41 transformative companies, including Denali Therapeutics (NASDAQ: DNLI), Evelo Biosciences (NASDAQ: EVLO), Foghorn Therapeutics (NASDAQ: FHTX), Moderna (NASDAQ: MRNA), Omega Therapeutics (NASDAQ: OMGA), Rubius Therapeutics (NASDAQ: RUBY), Sana Biotechnology (NASDAQ: SANA), and Seres Therapeutics (NASDAQ: MCRB). To date, Flagship has deployed over $2.9 billion in capital toward the founding and growth of its pioneering companies alongside more than $19 billion of follow-on investments from other institutions. Since its launch in 2000, the firm has, through its Flagship Labs unit, applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in more than $100 billion in aggregate value. For more info, visit About Flagship Pioneeringįlagship Pioneering conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability. The company currently has programs ongoing in several disease areas including those in metabolic disease, hematology, and immuno-oncology. As Cellarity’s medicines are created against many drivers of cellular disease instead of a single target, their approach is designed to drive higher clinical translatability and success and is applicable to a vast array of disease areas. Founded by Flagship Pioneering in 2017, Cellarity has developed unique capabilities combining high-resolution data, single-cell technologies, and machine learning to unravel complex disease biology and purposefully design breakthrough medicines. By shifting the focus from a single target to understanding the whole cell, Cellarity unravels complex disease biology to create treatments never before possible. The Cellarity platform provides critical insights into cellular dysfunction and reveals new biology through which we can address a range of diseases, including those which presently lack a known druggable target.Ĭellarity’s mission is to fundamentally redesign the way drugs are created. Cellarity has developed unique capabilities to link biology and chemistry with high dimensional, transcriptomic data to design medicines against the cellular signature of the disease. ![]() The company uses single-cell technologies to identify cellular drivers during the transition from health to disease and applies proprietary deep learning models to create drugs that reverse disease at the level of the cell. To create medicines, Cellarity looks beyond individual molecular targets and instead focuses on the whole cell. With this financing, we plan to advance our pipeline and showcase the immense possibilities of our approach." We have already made significant progress in confirming the unique capability of our platform with the development of compounds that have been validated in vitro and in vivo, including in higher species. "By shifting the focus from a single target to the underlying cellular dysfunction, our platform unravels the complexity of disease biology to create medicines never before possible. "We welcome our new investors and appreciate the continued support of our current investors," said Fabrice Chouraqui, PharmD, CEO of Cellarity and a CEO-Partner at Flagship Pioneering. The proceeds of the financing will be used to grow Cellarity’s talent base, strengthen its platform, and advance its pipeline toward the clinic. In addition to participation by Flagship Pioneering and other Series B investors, four new investors participated, including Kyowa Kirin Co. SOMERVILLE, Mass., October 04, 2022-( BUSINESS WIRE)- Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the completion of a $121 million Series C financing, bringing its total funding raised to date to $274 million. ![]()
0 Comments
Leave a Reply. |